Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 594

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 594
---
)

The consummation of the Acquisition Transactions is conditioned upon the satisfaction or waiver of certain closing conditions including the entering into and subsequent closing of an approved business combination agreement with a blank-check special purpose acquisition company.

The parties to the C&E Agreement have made customary representations and warranties and have also agreed to certain customary covenants with respect to, among others, the conduct of the business of Cerevast and Longevity prior to the closing of the Acquisitions Transactions.

First Amendment to the C&E Agreement

On January 25, 2023, the Company and each of its shareholders entered into an amendment to the C&E Agreements with Longevity pursuant to which certain provisions of the C&E Agreements were amended to, among other things: modify the aggregate valuation assigned to Longevity reflecting the Acquisition Transactions, modify the allocation of the transaction consideration among the Target Companies, modify the minimum cash balance at closing of the Business Combination, and modify certain representations, warranties, covenants, closing conditions, termination provisions, and other provisions of the C&E Agreements.

Second Amendment to the C&E Agreement

On June 26, 2023 the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to have a lock-up of 180 days for directors, officers and 5% or greater stockholders of the post-transaction company.

Third Amendment to the C&E Agreement

On August 29, 2023, the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to remove the minimum cash balance condition of $30 million.

Termination of C&E Agreement with Novakera, LLC

On August 8, 2024, Longevity terminated the C&E Agreement with Novokera LLC pursuant to Section 10.1(b) of the C&E Agreement due to multiple conditions not being satisfied or waived to close a business combination by October 25, 2023. Aegeria and Cerevast Medical, Inc. remained parties to the C&E Agreements and remained Target Companies.

Fourth Amendment to the C&E Agreement

On August 8, 2024, Longevity entered into amendments to the C&E Agreements with the remaining Target Companies and each of the Target Companies respective shareholders and unitholders pursuant to which certain provisions of the C&E Agreements were amended to, among other things: modify the aggregate valuation assigned to Longevity reflecting a business combination and modify the allocation of the transaction consideration among the Target Companies and Future